Healthcare Providers and Services
Company Overview of DIATHERIX Laboratories, Inc.
DIATHERIX Laboratories, Inc., a molecular diagnostic laboratory, offers diagnostic services for detection of infectious diseases. It uses target enriched multiplex polymerase chain reaction technology for precise detection of infectious diseases. The company provides nucleic acid extraction, template addition, and hybridization services. It offers its services to physicians and hospitals. DIATHERIX Laboratories, Inc. was incorporated in 2007 and is based in Huntsville, Alabama. As of June 11, 2015, DIATHERIX Laboratories, Inc. operates as a subsidiary of Eurofins Scientific SA.
601 Genome Way
Huntsville, AL 35806
Founded in 2007
Key Executives for DIATHERIX Laboratories, Inc.
Chairman and Chief Executive Officer
President and Chief Operating Officer
Chief Information Officer
Compensation as of Fiscal Year 2015.
DIATHERIX Laboratories, Inc. Key Developments
DIATHERIX Laboratories, Inc. Appoints Ruth W. Brinkley to its Board of Directors
Feb 12 15
DIATHERIX Laboratories, Inc. announced the appointment of Ruth W. Brinkley, FACHE, to its board of directors. Brinkley has more than 40 years of healthcare experience working in private, public, academic, community-based and healthcare organizations. She currently serves as president and chief executive officer of KentuckyOne Health and as senior vice president of operations for Catholic Health Initiatives.
DIATHERIX Laboratories, Inc. Receives Second Research Contract from FDA and HHS
Dec 16 14
DIATHERIX Laboratories, Inc. has been awarded a second federal contract to continue its work in the development of research methodologies designed to support the development of diagnostic tools to detect certain low prevalence pathogens. The contract is a joint award from the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) to support the development of diagnostic devices/platforms to detect high priority pathogens, as classified by the National Institute of Allergy and Infectious Diseases (NIAID). Diatherix's research focuses on three NIAID pathogens: Francisella tularensis, Escherichia coli, and Babesia microti. Though not prevalent in the natural environment, the pathogens are prioritized by NIAID because of the ease with which they can be disseminated or transmitted; the mortality rates and public health impact they can generate; their potential to cause public panic and social disruption; and the special actions that are required for public health preparedness. For instance, F. tularensis has a low infectious dose, is highly virulent, and is easily spread by aerosol; as such, it is classified by the NIAID and the U.S. Department of Homeland Security as a Category A Priority pathogen/biological agent that poses high risk to national security and public health. The low prevalence of these pathogens complicates the development of diagnostic tools to aid in their detection, as sufficient clinical samples may not be available to conduct the clinical sensitivity studies required for Food and Drug Administration (FDA) clearance. To address this regulatory and scientific challenge, the FDA is exploring the use of "spiked" clinical samples special lab samples in which the pathogen being studied is introduced at increased or enriched levels to support sensitivity studies for the evaluation of diagnostic devices.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 1, 2015
Most Searched Private Companies
Sponsored Financial Commentaries